Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138596 | 0.88 | TLR7 (0.41) | TLR7PDE4BPDE4DRAB9AALDH1A1 | |
| SCHEMBL29696120 | 0.81 | NPC1 (0.39) | TLR7PDE4BPDE4DRAB9AKDM4E | |
| SCHEMBL442638 | 0.81 | NPC1 (0.39) | TLR7PDE4BPDE4DRAB9AKDM4E | |
| SCHEMBL1138595 | 0.76 | MRGPRX4 (0.40) | RAB9AALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL447507 | 0.71 | NPC1 (0.38) | TLR7RAB9AKDM4ELMNANPC1 | |
| SCHEMBL25247534 | 0.68 | TLR7 (0.38) | TLR7RAB9ALMNANPC1KMT2A | |
| SCHEMBL1138695 | 0.68 | NPC1 (0.37) | TLR7RAB9AALDH1A1KDM4ELMNA | |
| SCHEMBL108876 | 0.67 | L3MBTL1 (0.62) | TLR7ALDH1A1KDM4ELMNAHTT | |
| SCHEMBL29396522 | 0.67 | BRD4 (0.61) | RAB9AALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL1240286 | 0.67 | BRD4 (0.61) | RAB9AALDH1A1SMN1; SMN2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1865968-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-20060217347-A1 | Topical formulations of borinic acid antibiotics and their methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006102604-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| EP-2437854-B1 | COMPOSITIONS COMPRISING BORINIC ESTERS | COLGATE PALMOLIVE CO (US) | 2018-08-08 | — | — | EP | disclosed |
| US-8852559-B2 | Borinic compositions | COLGATE-PALMOLIVE COMPANY (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2437855-A2 | BORINIC COMPOSITIONS | Colgate-Palmolive Company (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2437854-A2 | BORINIC COMPOSITIONS | Colgate-Palmolive Company (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120064017-A1 | BORINIC COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120052025-A1 | BORINIC COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010141693-A2 | BORINIC COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141694-A2 | BORINIC COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-1865968-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060217347-A1 | Topical formulations of borinic acid antibiotics and their methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006102604-A2 | TOPICAL FORMULATIONS OF BORINIC ACID ANTIBODIES AND THEIR METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217347-A1 | Topical formulations of borinic acid antibiotics and their methods of use | CUTA, BROX, BTD | TLR7 161/4885PDE4B 1729/4885PDE4D 2161/4885 |
| US-20120064017-A1 | BORINIC COMPOSITIONS | BACH1, FHIT, BPNT1 | TLR7 1475/4885PDE4B 4338/4885PDE4D 4710/4885 |
| US-20120052025-A1 | BORINIC COMPOSITIONS | CCL11, BDKRB2, BTD | TLR7 516/4885PDE4B 878/4885PDE4D 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.